Tirzepatide vs Semaglutide: Which GLP-1 Is Right for You?

By Verum Health Medical Team  ·  April 1, 2026  ·  8 min read

Two medications have fundamentally changed the weight loss landscape: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Both are weekly injectables. Both produce significant, sustained weight loss. And both are now available through physician-prescribed compounding pharmacies at a fraction of brand-name pricing.

So which one is right for you? The answer depends on your metabolic profile, how much weight you're looking to lose, your side effect tolerance, and what your physician finds on your labs. Here's the clinical breakdown.

Mechanism of Action: One Receptor vs. Two

This is the core difference. Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide-1, a hormone released after eating that signals satiety, slows gastric emptying, and stimulates insulin secretion. GLP-1 agonism is powerful. It's why semaglutide produces 15–17% average body weight reduction in the STEP trials.

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It hits both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is an incretin hormone that enhances the GLP-1 satiety signal and also plays a role in fat cell metabolism and adipogenesis. The dual mechanism appears to be additive — the SURMOUNT trials showed tirzepatide producing 20–22% average body weight reduction at the highest dose, outperforming semaglutide head-to-head in most comparative analyses.

Efficacy: The Numbers

In head-to-head comparisons, tirzepatide consistently produces more weight loss. That said, "more" isn't always the right criterion. If you've had significant GI side effects on GLP-1 agonists before, or if you're starting at a lower weight with a more modest goal, semaglutide at a conservative dose may be the better clinical choice.

Side Effect Profile

Both medications share a similar GI side effect profile — nausea, constipation, and occasional vomiting are the most common, particularly during dose escalation. These typically improve after the first 4–8 weeks as your body adjusts.

Where they differ:

• Tirzepatide tends to produce slightly more nausea during the ramp-up phase, but some patients report less nausea at steady-state doses compared to semaglutide
• Semaglutide has a longer track record (more years of post-market data), which gives some patients and physicians more comfort
• Both carry a class warning for thyroid C-cell tumors (based on rodent data — no clear signal in humans to date) and are contraindicated in patients with personal or family history of MTC or MEN2
• Read our detailed guide to managing semaglutide side effects →

Dosing and Titration

Semaglutide titration schedule (weekly subcutaneous injection):

• Weeks 1–4: 0.25mg
• Weeks 5–8: 0.5mg
• Weeks 9–12: 1.0mg
• Weeks 13–16: 1.7mg
• Week 17+: 2.4mg (maintenance)

Tirzepatide titration schedule (weekly subcutaneous injection):

• Weeks 1–4: 2.5mg
• Weeks 5–8: 5mg
• Every 4 weeks, increase by 2.5mg as tolerated
• Maximum: 15mg/week

Compounded versions of both medications allow physicians to customize dosing more precisely than the fixed-step brand-name titration schedules. This flexibility is particularly useful for patients who are highly sensitive to GI effects — smaller incremental increases slow down the ramp and dramatically improve tolerability.

Cost: Compounded vs. Brand Name

Brand-name semaglutide (Wegovy) and tirzepatide (Zepbound) list at $1,200–$1,400/month without insurance. Insurance coverage is inconsistent and often requires prior authorization with specific BMI thresholds.

Compounded semaglutide and tirzepatide from licensed 503A pharmacies are significantly more affordable — typically $200–$400/month depending on dose. These are the same active pharmaceutical ingredients, compounded under USP standards, dispensed with a physician prescription. At Verum Health, every patient receives a licensed physician consultation and pharmacy-direct shipment. See our full protocol pricing →

Which One Should You Choose?

This is genuinely a physician decision, not a self-selection one — your metabolic labs, cardiovascular risk profile, and weight loss goals all factor in. But here's a rough framework our medical team uses:

• Choose semaglutide if: You want a proven medication with a longer post-market track record, you're targeting 10–15% weight loss, or you've tolerated GLP-1 agonists before
• Choose tirzepatide if: You're targeting more aggressive weight loss (15–22%), you have insulin resistance or pre-diabetes (GIP receptor agonism adds meaningful metabolic benefit), or semaglutide didn't produce adequate results
• Either medication requires ongoing physician oversight, quarterly labs, and a structured protocol — not a prescription and a goodbye

Ready to find out which protocol fits your profile? Our physician consultations are async — no waiting room, no scheduling hassle. You'll have a protocol recommendation within 24 hours of your intake.